Skip to content
Menu

Lantheus Holdings, Inc. LNTH

Full chart Compare
Set alert

Price alert · LNTH

All alert types
102.10 USD 0.00 (+0.00%)

Regular-session close

102.10 0.00 0.00%

After hours · Nov 20, 4:26 PM ET

102.07 Day range 102.40
53.38 52-week range 111.86
YTD
+53.42%
1 year
+90.52%

5D +0.61 (+0.60%)

101.25101.50101.75102FriMonTueWedThu102.00
Market cap
6.68B
Revenue (ttm)
1.56B
Profit margin
17.28%
EPS (ttm)
4.02
Shares out
65.40M
P/E ratio
25.40
Forward P/E
15.34
YTD return
+53.42%
1-year return
+90.52%
50-day average
100.43
Volume
1.07M
Avg volume
1.02M
Open
102.10
Previous close
102.10
Day's range
102.07 – 102.40
52-week range
53.38 – 111.86
Beta
0.03
Analysts
Hold
Price target
105.99 (+3.8%)
Earnings date
Feb 25, 2027

Key statistics

200-day average
93.82
Enterprise value
6.62B
Price / sales
4.27
Price / book
4.92
Revenue growth
1.50%
Free cash flow
403.71M
Total cash
683.61M
Total debt
624.28M
Return on equity
21.81%
Short % of float
6.52%

Fundamental scorecard

16 of 25 checks passed on LNTH’s reported financials

ValueGrowthProfitabilityHealthDividend

16of 25 checks passed

  • Value 2 of 5
  • Growth 5 of 5
  • Profitability 4 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
LNTH Revenue — quarterly 389.91M
LNTH Net income — quarterly 22.37M
LNTH EPS — quarterly 0.34

Earnings

LNTH recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 20261.31———
Nov 5, 2026Sep 30, 20261.231.68+0.45+36.59%
Aug 6, 2026Jun 30, 20261.301.55+0.25+19.23%
May 7, 2026Mar 31, 20261.251.46+0.21+16.80%
Feb 26, 2026Dec 31, 20251.181.67+0.49+41.53%
Nov 6, 2025Sep 30, 20251.271.270.000.00%

Upgrades / downgrades

LNTH analyst upgrades and downgrades
DateFirmActionFromTo
Oct 13, 2026MizuhodownOutperformNeutral
Aug 4, 2026Truist SecuritiesdownBuyHold
Aug 4, 2026CJS SecuritiesdownMarket OutperformMarket Perform
Aug 3, 2026William BlairdownOutperformMarket Perform
Aug 3, 2026TD CowendownBuyHold
Jul 29, 2026MizuhomainOutperformOutperform

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States
Website
lantheus.com

News

Your note

Sign in to keep a note on LNTH — it syncs with the Stock Master app.

Insider holders

LNTH insider holders
InsiderRelationLatest transactionDateShares held
BLANCHFIELD PAULPresidentSaleAug 12, 2025108,214
DINKELBORG LUDGEROfficerStock Award(Grant)Mar 4, 202635,731
FARALLON PARTNERS, L.L.C.Beneficial Owner of more than 10% of a Class of SecuritySaleAug 19, 20250
HEINO MARY ANNEChief Executive OfficerStock Award(Grant)Mar 1, 2026589,195
LENO SAMUEL RDirectorStock Award(Grant)May 13, 202667,246
MARKISON BRIAN AChief Executive OfficerStock Award(Grant)Mar 4, 2025232,420

Institution ownership

LNTH institution ownership
Holder% heldSharesValueReported
Blackrock Inc.13.24%8,657,364883.92MSep 29, 2026
Pentwater Capital Management Lp5.96%3,900,000398.19MSep 29, 2026
American Century Companies Inc4.90%3,203,378327.06MSep 29, 2026
Vanguard Portfolio Management LLC4.79%3,129,711319.54MSep 29, 2026
Farallon Capital Management LLC4.76%3,111,254317.66MSep 29, 2026
Vanguard Capital Management LLC4.47%2,920,187298.15MSep 29, 2026

Fund ownership

LNTH fund ownership
Holder% heldSharesValueReported
American Century ETF Trust-Avantis U.S. Small Cap Value ETF3.97%2,593,343264.78MSep 29, 2026
iShares Trust-iShares Core S&P Mid-Cap ETF3.56%2,325,136237.40MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.16%2,065,879210.93MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.58%1,687,913172.34MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.28%1,493,665152.50MJun 29, 2026
JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund1.73%1,132,936115.67MSep 29, 2026